ISO

Isofol Medical is a Swedish clinical-stage pharmaceutical company focused on improving the efficacy of standard-of-care chemotherapy for advanced colorectal cancer and other solid tumors. The company's lead drug candidate, arfolitixorin, is a stabilized folate derivative designed to enhance the cytotoxic effect of 5-fluorouracil (5-FU) by providing a direct source of the active co-factor required for thymidylate synthase inhibition. Unlike traditional folates like leucovorin, arfolitixorin does not require complex metabolic activation, potentially offering a more potent and consistent therapeutic benefit. Isofol is currently evaluating arfolitixorin in clinical trials to establish it as a superior alternative to current folate-based treatments in oncology.